This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LeBlanc, G. A. Articles by Waxman, D. J. Search for Related Content PubMed PubMed Citation Articles by LeBlanc, G. A. Articles by Waxman, D. J.

Mechanisms of Cyclophosphamide Action on Hepatic P-450 Expression¹

Department of Biological Chemistry and Molecular Pharmacology, and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115

Cyclophosphamide was administered to adult male rats (130 mg/kg, single i.p. injection) and its effects on the P-450 enzymes that contribute to the activation of this drug in rat liver were then assessed. P-450-mediated cyclophosphamide 4-hydroxylase activity in isolated rat liver microsomes decreased by approximately 70% over a 9-day period following drug treatment. This decrease was due to the loss of cytochrome P-450 form 2c (IIC11), a major contributor to cyclophosphamide 4-hydroxylation in untreated male rat liver, while the other major hepatic cyclophosphamide 4-hydroxylase, P-450 PB-1 (IIC6), was largely unaffected. The loss of P-450 2c activity did not result from a decrease in P-450 reductase or from direct inactivation of the P-450 protein by cyclophosphamide or its metabolites, but rather was due to a reduction in hepatic P-450 2c protein and mRNA levels. Hepatic P-450 2a (IIIA2)and P-450 RLM2 (IIA2) were also suppressed by cyclophosphamide treatment. Serum testosterone, which contributes to the expression of P-450s 2c, 2a, and RLM2, was severely depleted in the cyclophosphamide-treated rats; however, this loss was not the direct cause of the decreases in these hepatic P-450s, since the decreases were not reversed upon restoration of normal testosterone levels by human chorionic gonadotropin stimulation of testicular androgen production. In contrast to the suppression of these testosterone-dependent P-450s, P-450 3 (IIA1), P-450j (IIe1), and the P-450-independent microsomal enzyme steroid 5-reductase were each elevated in rat liver following cyclophosphamide administration. In contrast to P-450 3 and steroid 5-reductase, however, the elevation of P-450j protein was transient and was not accompanied by an increase in P-450j-associated hepatic microsomal aniline hydroxylase activity. In vitro experiments revealed that P-450j was severalfold more susceptible to inactivation by the cyclophosphamide metabolite acrolein as compared with P-450 3. These observations suggest that P-450j protein is induced by cyclophosphamide treatment but that the protein is inactivated by the cyclophosphamide metabolite acrolein. These findings establish that cyclophosphamide treatment can modulate hepatic P-450 activities through multiple mechanisms and in a manner that may alter P-450 metabolism of cyclophosphamide and perhaps other anticancer drugs that undergo bioactivation in the liver.

¹ Supported in part by Postdoctoral Fellowship Award 1F32-CA08259 [G. A. L.] and Grant CN-14 from the American Cancer Society [D. J. W.].

² Present address: Toxicology Department. Box 7633. North Carolina State University, Raleigh, NC 27695.

³ To whom all correspondence should be addressed, at Dana-Farber Cancer Institute, JF-525, 44 Binney Street, Boston, MA 02115.

Received 3/29/90. Accepted 6/19/90.

This article has been cited by other articles:

				P. Afsharian, Y. Terelius, Z. Hassan, C. Nilsson, S. Lundgren, and M. Hassan The Effect of Repeated Administration of Cyclophosphamide on Cytochrome P450 2B in Rats Clin. Cancer Res., July 15, 2007; 13(14): 4218 - 4224. [Abstract] [Full Text] [PDF]

				J. A. Nishime, R. W. Wang, J. H. Lin, and M. Chiba Modulation of Rat Cytochrome P-450 by an Investigational HIV Protease Inhibitor Drug Metab. Dispos., September 1, 1999; 27(9): 972 - 976. [Abstract] [Full Text]

				D. A Tweddle, K. P Windebank, Q. C. Hewson, and S M. Yule Drug points: Cyclosporin neurotoxicity after chemotherapy BMJ, April 24, 1999; 318(7191): 1113 - 1113. [Full Text]

				R. De Salvia, M. Fiore, T. Aglitti, F. Festa, R. Ricordy, and R. Cozzi Inhibitory action of melatonin on H2O2- and cyclophosphamide-induced DNA damage Mutagenesis, January 1, 1999; 14(1): 107 - 112. [Abstract] [Full Text] [PDF]